This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Earlier this year, Xarelto Defendants Janssen, Johnson & Johnson and Bayer filed a Motion for Summary Judgment asking the MDL Court to rule in their favor on certain of the Plaintiffs' claims.
Published on Friday, April 21, 2017 by Staff
As ordered by MDL (Multi-District Litigation) Judge Eldon Fallon of the United States District Court for the Eastern District of Louisiana, four (4) Xarelto bellwether trials are scheduled to take place over the next few months.
Published on Saturday, April 15, 2017 by Staff
The results of a key "non-inferiority" clinical trial in which the safety and efficacy of Xarelto® (rivaroxaban) were compared to warfarin are being reviewed by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMEA).
Published on Wednesday, February 24, 2016 by Staff
Pharmaceutical companies use various offers of discounts and benefits to collect information from patients. The scope of the information collected varies and depends upon the particular program or benefit being offered.
Published on Monday, December 28, 2015 by Staff
A recent study that looked at Department of Defense electronic medical records was reported in poster fashion at a recent meeting of the American Heart Association.
Published on Monday, December 21, 2015 by Staff
Health Canada, the regulatory body responsible for drug safety in Canada, recently conducted a safety review of Xarelto® after learning of 16 reports of patients who suffered liver injury associated with the use of Xarelto®
Published on Sunday, September 6, 2015 by Staff
On December 12, 2014, the Federal Judicial Panel on Multi-District Litigation issued its Order consolidating all federal Xarelto® cases before Judge Edward Fallon sitting in the Eastern District of Louisiana.
Published on Sunday, October 12, 2014 by Staff
In June of 2013, the FDA's Office of Prescription Drug Promotion (OPDP) issued a cease and desist letter to Johnson & Johnson, the manufacturer of Xarelto®.
Published on Sunday, October 12, 2014 by Staff
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.